Washington Prime Group Inc. will replace UTi Worldwide Inc. (UTIW) in the S&P MidCap 400, and UTi Worldwide will replace ArQule Inc (NASDAQ:ARQL) in the S&P SmallCap 600 effective after the close of trading on Wednesday, May 28. S&P 100 & 500 constituent Simon Property Group Inc. (SPG) is spinning off Washington Prime Group to shareholders in a transaction expected to be completed after the close of trading on that date. Post spin, Simon Property Group will remain in the S&P 100 & 500. UTi Worldwide is ranked # 400 in the S&P MidCap 400 and is more appropriate for the S&P SmallCap 600. ArQule is ranked #600 in the S&P SmallCap 600 and is no longer representative of that index. ArQule, Inc. (NASDAQ:ARQL) weekly performance is -3.42%. On last trading day company shares ended up $1.41. Analysts mean target price for the company is $3.25. ArQule, Inc. (NASDAQ:ARQL) distance from 50-day simple moving average (SMA50) is -20.35%.
On May 7, AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) reported its first quarter 2014 financial results and provided an update on its progress toward achieving its strategic plan. Net loss for Q1 2014 was $6.5 million or a loss of $0.12 per basic and diluted net loss per share compared with net loss of $34.1 million or a loss of $0.69 per basic and diluted net loss per share for Q1 2013. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) ended the day on $1.07. Its return on assets is -50.60%. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) quarterly performance is -43.09%.
Investment analysts at Guggenheim decreased their price target on shares of Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG) from $15.00 to $13.00 in a note issued to investors on Friday, AnalystRatings.Net reports. Guggenheim’s target price would suggest a potential upside of 129.68% from the company’s current price. Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG) shares moved down -2.11 % in last trading session and was closed at $4.17, while trading in range of $4.09 – $4.50. Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG) year to date (YTD) performance is -56.20%.
On May 20, TrovaGene Inc (NASDAQ:TROV) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock. And for technical investors there is some hope when looking at TROV given that, according to its RSI reading of 24.68, it is now in oversold territory. TrovaGene Inc (NASDAQ:TROV) ended the last trading day at $3.55. Company weekly volatility is calculated as 7.08% and price to cash ratio as 2.60. TrovaGene Inc (NASDAQ:TROV) showed a negative weekly performance of -10.13%.
Cerulean Pharma Inc. (NASDAQ:CERS) announced that the underwriters for its initial public offering of common stock have exercised their over-allotment option and purchased an additional 1,069,715 shares. The additional shares were sold at the public offering price of $7.00 per share, before underwriting discounts. The closing occurred on May 7, 2014, bringing the total number of shares sold by Cerulean in the initial public offering to 9,569,715 shares and the total gross proceeds to approximately $67 million before underwriting discounts and offering expenses. Cerus Corporation (NASDAQ:CERS) weekly performance is -11.61%. On last trading day company shares ended up $4.20. Analysts mean target price for the company is $12.50. Cerus Corporation (NASDAQ:CERS) distance from 50-day simple moving average (SMA50) is -14.75%.
Leave a Reply